SLC2A1 and esophageal squamous cell carcinoma: It has been suggested that inhibition of GLUT1 by either RNA interference or N4-[1-(4-cyanobenzyl)-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-fluoroquinoline-2,4-dicarboxamide (BAY-876, a specific GLUT1 inhibitor) could resensitize cisplatin to esophageal squamous cell carcinoma (ESCC) [28].